Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts. Show more
Location: 21 Hickory Drive, Waltham, MA, 02451, United States | Website: https://www.sionnatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
900.8M
52 Wk Range
$7.25 - $25.19
Previous Close
$20.94
Open
$20.87
Volume
51,638
Day Range
$20.12 - $20.87
Enterprise Value
504.8M
Cash
269.7M
Avg Qtr Burn
-13.98M
Insider Ownership
7.20%
Institutional Own.
93.43%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SION-719 Details Cystic fibrosis | Phase 2a Initiation | |
SION-451 Details Cystic fibrosis | Phase 1 Initiation |